Journal
CARDIOLOGY CLINICS
Volume 34, Issue 3, Pages 413-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccl.2016.04.003
Keywords
Pulmonary hypertension; Chronic obstructive pulmonary disease; Interstitial lung disease; Obstructive sleep apnea; Endothelin receptor antagonist; Phosphodiesterase inhibitor; Prostacyclin; Soluble guanylate cyclase stimulator
Categories
Funding
- National Heart, Lung, and Blood Institute [RO1 HL 123965]
- Bayer
- Gilead
- Lung Biotechnology
- United Therapeutics
Ask authors/readers for more resources
Pulmonary hypertension (PH) associated with chronic lung disease (WHO group 3) is the second leading cause of PH and is associated with increased morbidity and mortality. Elevation of pulmonary arterial pressure (PAP) is usually moderate and correlates with severity of lung disease. In a small minority, PAP may approach that seen in WHO group 1 pulmonary arterial hypertension (PAH). Current medications for treating PAH have not shown benefit in controlled trials of group 3 PH and their routine use is discouraged. Patients with severe group 3 PH should be considered for referral to expert centers or entry into clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available